Skip to main content

Published locations for EC approves nivolumab for relapsed/refractory cHL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. EC approves nivolumab for relapsed/refractory cHL

User login

  • Reset your password
  • /content/ec-approves-nivolumab-relapsed/refractory-chl
  • /hematology-oncology/article/188717/lymphoma-plasma-cell-disorders/ec-approves-nivolumab-relapsed/refractory-chl
  • /hematologytimes/article/188717/lymphoma-plasma-cell-disorders/ec-approves-nivolumab-relapsed